Recent News Releases
For investor-related news, see our ASX releases here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Apr 11, 2019
Agreement to jointly commercialise the new diabetic kidney disease (DKD) indication for INVOKANA® (canagliflozin) in the US Only diabetes treatment indicated to slow down the progression of DKD...
-
Apr 9, 2019Leading global biotech company brings innovative therapies for life-threatening medical conditions to UAE
Dubai, UAE - 9 April, 2019 – CSL Behring, a global biotherapeutics leader, has inaugurated its regional headquarters at Dubai Science Park (DSP), a holistic science-focused business community...
-
Mar 26, 2019CSL Behring announced today that Japan’s Ministry of Health, Labour and Welfare has approved two of its immunoglobulin therapies for the treatment of patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): Hizentra® and Privigen®
26 Mar 2019 Hizentra® [human normal immunoglobulin, 20%, subcutaneous] is the first and only subcutaneous immunoglobulin approved for the maintenance treatment of CIDP in Japan, based on findings...
Mar 15, 2019MELBOURNE, Australia - CSL today announced its continued partnership with the National Youth Science Forum (NYSF) signing a new three-year agreement in support of programs that encourage life-long...
-
Mar 14, 2019
VIFOR PHARMA GROUP REPORTS STRONG 2018 RESULTS, EXCEEDING RAISED GUIDANCE THE VIFOR PHARMA GROUP REPORTED A STRONG SALES AND PROFIT PERFORMANCE IN 2018 WITH CONTINUED SOLID GROWTH FROM ITS THREE...
-
Feb 4, 2019Reinforces Commitment to Providing Global Bleeding Disorders Community with Access to Care and Efforts to Increase Awareness
04 Feb 2019 MONTREAL and KING OF PRUSSIA, Pa. – 4 February 2019 – The World Federation of Hemophilia (WFH) and global biotherapeutics leader CSL Behring today announced that the company has...
-
Jan 24, 2019
Companies plan to file for full marketing approval to EMA and FDA in 2020 MOUNTAIN VIEW, Calif. and ZURICH, 24 January, 2019 – ChemoCentryx, Inc. and Vifor Fresenius Medical Care Renal Pharma...
-
Jan 22, 2019
Re-analysis of the PIVOTAL data by the investigators has revealed that proactive, high-dose Venofer® compared to reactive, low-dose Venofer® resulted in: Superiority and statistically...
-
Jan 16, 2019Forbes Recognizes the Global Biotechnology Leader in its Top 50 Best Employers for Diversity 2019
16 Jan 2019 KING OF PRUSSIA, Pa. – January 16, 2019 – Forbes magazine has named global biotechnology leader CSL Limited as one of The Best Employers for Diversity in the United States. CSL,...
-
Jan 14, 2019
This news release is intended for Health Professional media only. Seqirus to launch its cell-based influenza vaccine in Europe for the 2019-20 season Real-world data indicates cell-based influenza...